EGFR and leukemia: In contrast to chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-EGFR] in dual-combination with epirubicin-(C3-amide)-[anti-HER2/neu] would likely have been higher if it had been measured utilizing an entirely different neoplastic cell type such as pancreatic carcinoma,[166] small-cell lung carcinoma,[167] neuroblastoma,[168] or leukemia/lymphoid[123;169] populations because of their relatively higher gemcitabine sensitivity.